1. Home
  2. PD vs ANAB Comparison

PD vs ANAB Comparison

Compare PD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$12.55

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.11

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PD
ANAB
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
PD
ANAB
Price
$12.55
$44.11
Analyst Decision
Hold
Buy
Analyst Count
10
12
Target Price
$17.10
$58.09
AVG Volume (30 Days)
1.6M
501.4K
Earning Date
11-25-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.63
N/A
Revenue
$489,207,000.00
$169,467,000.00
Revenue This Year
$8.16
$135.45
Revenue Next Year
$3.88
N/A
P/E Ratio
$7.77
N/A
Revenue Growth
7.01
196.42
52 Week Low
$11.13
$12.21
52 Week High
$20.00
$52.47

Technical Indicators

Market Signals
Indicator
PD
ANAB
Relative Strength Index (RSI) 43.49 46.84
Support Level $12.06 $42.00
Resistance Level $12.77 $47.36
Average True Range (ATR) 0.38 2.37
MACD 0.03 -0.95
Stochastic Oscillator 35.06 19.77

Price Performance

Historical Comparison
PD
ANAB

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: